Search
Abstract
Telomerase is a reverse transcriptase enzyme involved in DNA synthesis at the end of linear chromosomes. Unlike in most other cells, telomerase is reactivated most cancerous cells and, therefore, has become a promising new anticancer target. Despite extensive research, direct telomerase inhibitors have yet not been introduced to the clinics because of the complexity of this enzyme. Structures of this protein from simple organisms and human homology models are currently available and have been used in structure-based drug design efforts to find potential inhibitors. Different is silico strategies have been applied and different chemical groups have been explored. Here, we provide an overview of recent discoveries.
Citations
-
1 1
CrossRef
-
0
Web of Science
-
1 3
Scopus
Cite as
Full text
- Publication version
- Accepted or Published Version
- License
-
open in new tab
Keywords
Details
- Category:
- Articles
- Type:
- artykuły w czasopismach
- Published in:
-
DRUG DISCOVERY TODAY
no. 25,
pages 1213 - 1222,
ISSN: 1359-6446 - Language:
- English
- Publication year:
- 2020
- Bibliographic description:
- Bagiński M., Serbakowska K.: In silico design of telomerase inhibitors.// DRUG DISCOVERY TODAY -Vol. 25,iss. 7 (2020), s.1213-1222
- DOI:
- Digital Object Identifier (open in new tab) 10.1016/j.drudis.2020.04.024
- Sources of funding:
- Verified by:
- Gdańsk University of Technology
seen 170 times